Loeb H S, Danoviz J, Miller A, Gunnar R M
Am Heart J. 1983 Jun;105(6):906-10. doi: 10.1016/0002-8703(83)90388-5.
The effects of oral dipyridamole administration (150 mg) on coronary hemodynamics, myocardial metabolism, and pacing threshold were studied in 10 patients with significant coronary artery disease (CAD). Following dipyridamole through 120 minutes, there was no significant change in resting heart rate, arterial pressure, coronary venous flow, coronary resistance, myocardial lactate extraction, or myocardial oxygen consumption. Rapid atrial pacing performed before and at 60, 90, and 120 minutes after dipyridamole failed to demonstrate any significant reduction in pacing threshold or evidence of increased ischemia after dipyridamole. Blood dipyridamole levels showed variable and slow absorption which probably explains the difference between intravenous and oral dipyridamole on coronary dynamics and myocardial response to pacing.
对10例患有严重冠状动脉疾病（CAD）的患者，研究了口服双嘧达莫（150毫克）对冠状动脉血流动力学、心肌代谢和起搏阈值的影响。在给予双嘧达莫后120分钟内，静息心率、动脉压、冠状静脉血流、冠状动脉阻力、心肌乳酸摄取或心肌氧耗均无显著变化。在给予双嘧达莫前以及给药后60、90和120分钟进行快速心房起搏，未显示起搏阈值有任何显著降低，也没有证据表明双嘧达莫给药后缺血增加。血液中双嘧达莫水平显示吸收可变且缓慢，这可能解释了静脉注射和口服双嘧达莫在冠状动脉动力学和心肌对起搏反应方面的差异。
